Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756
Authors:
Open Access
- 1 October 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (10) , 2865-2870
Abstract
Existing quinolones are known to target the type II topoisomerases in bacteria. In order to determine which of these targets are of key importance in Streptococcus pneumoniae treated with BMS-284756 (T-3811ME), a novel des-F(6) quinolone, resistant mutants were selected in several steps of increasing resistance by plating pneumococci on a series of blood agar plates containing serial twofold-increasing concentrations of drug. After incubation, colonies that arose were selected and passaged twice on antibiotic-containing media at the selection level. Mutants generally showed increases in resistance of four- to eightfold over the prior level of susceptibility. Mutants in the next-higher level of resistance were selected from the previous round of resistant mutants. Subsequently, chromosomal DNA was prepared from parental (R6) pneumococci and from at least three clones from each of four levels of increasing antibiotic resistance. Using PCR primers, 500- to 700-bp amplicons surrounding the quinolone resistance determining regions (QRDR) of gyrA , gyrB , parC, and parE genes were prepared from each strain. Internal primers were used to sequence both DNA strands in the regions of approximately 400 bp centered on the QRDR. Mutations identified with increasing levels of resistance included changes in GyrA at Ser-81 and Glu-85 and changes in ParC at Ser-79 and Asp-83. Changes in GyrB and ParE were not observed at the levels of resistance obtained in this selection. The resistance to comparator quinolones (levofloxacin, ciprofloxacin, and moxifloxacin) also increased in four- to eightfold steps with these mutations. The intrinsically greater level of antibacterial activity and thus lower MICs of BMS-284756 observed at all resistance levels in this study may translate to coverage of these resistant pneumococcal strains in the clinic.Keywords
This publication has 41 references indexed in Scilit:
- Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?Journal of Antimicrobial Chemotherapy, 2000
- Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacinJournal of Medical Microbiology, 1999
- Mechanisms of fluoroquinolone resistanceDrug Resistance Updates, 1999
- Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998Drugs, 1999
- Bacterial Topoisomerases, Anti‐Topoisomerases, and Anti‐Topoisomerase ResistanceClinical Infectious Diseases, 1998
- DNA Gyrase and Topoisomerase IV on the Bacterial Chromosome: Quinolone-induced DNA CleavageJournal of Molecular Biology, 1996
- Structure-activity and structure-side-effect relationships for the quinolone antibacterialsJournal of Antimicrobial Chemotherapy, 1994
- New topoisomerase essential for chromosome segregation in E. coliCell, 1990
- Transcription generates positively and negatively supercoiled domains in the templateCell, 1988
- DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acidJournal of Molecular Biology, 1979